Cell type-specific roles for tissue plasminogen activator released by neurons or microglia after excitotoxic injury.
Tissue plasminogen activator (tPA) plays important roles in the brain after excitotoxic injury. It is released by both neurons and microglia and mediates neuronal death and microglial activation. Mice lacking tPA are resistant to excitotoxicity and show very limited microglial activation. Activated microglia are neurotoxic in culture, but this phenomenon is not well documented in vivo. To further understand the sequence of events through which tPA mediates microglial activation and neurodegeneration, we have generated mice that exhibit restricted expression of tPA through introduction of tPA transgenes under the control of neuronal- or microglial-specific promoters into tPA-deficient mice. Neither strain of transgenic mice shows abnormal brain morphology or inflammation in the absence of injury, and unilateral intrahippocampal kainate injections into the transgenic mice induced excitotoxicity and microglial activation reminiscent of wild-type mice. However, there are differences in the kinetics of the resulting pathology. The neuronal tPA-expressing mice exhibit accelerated microglial activation compared with wild-type or microglial tPA-expressing mice. However, microglial tPA-expressing mice exhibit greater neurodegeneration. These data suggest a model in which tPA plays different roles after kainate injection depending on whether it is released by neurons or microglia. We propose that tPA, initially secreted from injured neurons, acts as a cytokine to activate microglia at the site of injury. These activated microglia then secrete additional tPA, which promotes extracellular matrix degradation, neurodegeneration, and self-proliferation. We suggest that an approach to attenuate microglia-mediated neuronal death in vivo might be to pharmacologically prevent microglial activation.
Siao
Chia-Jen
CJ
Department of Pharmacological Sciences, Program in Molecular and Cellular Pharmacology, University Medical Center at Stony Brook, Stony Brook, New York 11794-8651, USA.
Fernandez
Susana R
SR
Tsirka
Stella E
SE
D000818:Animals; D002452:Cell Count; D002478:Cells, Cultured; D018450:Disease Progression; D015870:Gene Expression; D016236:Genes, fms; D020022:Genetic Predisposition to Disease; D007608:Kainic Acid; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D017628:Microglia / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D019636:Neurodegenerative Diseases / Q000139:chemically induced / Q000235:genetics* / Q000473:pathology; D016900:Neurofilament Proteins / Q000235:genetics; D009474:Neurons / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D009498:Neurotoxins; D009928:Organ Specificity / Q000235:genetics; D011401:Promoter Regions, Genetic; D010959:Tissue Plasminogen Activator / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*
D016900:Neurofilament Proteins; D009498:Neurotoxins; C044882:neurofilament protein L; D010959:Tissue Plasminogen Activator; D007608:Kainic Acid